Immediate Impact
2 by Nobel laureates 55 standout
Citing Papers
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
2023 Standout
Accelerating antiviral drug discovery: lessons from COVID-19
2023 Standout
Works of Angela Worth being referenced
1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER
2013
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Angela Worth | 69 | 261 | 223 | 172 | 12 | 387 | |
| Matthew W. Lamb | 117 | 167 | 149 | 58 | 12 | 355 | |
| Minoru Ayada | 30 | 264 | 166 | 81 | 22 | 424 | |
| Betty Jane S. Gerstley | 31 | 173 | 261 | 34 | 10 | 435 | |
| I Jiménez‐Nácher | 46 | 78 | 120 | 239 | 12 | 361 | |
| Carol Goulding | 80 | 134 | 145 | 36 | 15 | 422 | |
| Erica D. Greanya | 25 | 165 | 193 | 96 | 20 | 347 | |
| Pedro Martínez-Odriozola | 80 | 188 | 209 | 81 | 8 | 457 | |
| Hosoon P. Dincsoy | 34 | 53 | 182 | 115 | 16 | 435 | |
| Amelia Warner | 17 | 235 | 158 | 51 | 10 | 393 | |
| J P Petite | 65 | 50 | 82 | 40 | 26 | 412 |
All Works
Login with ORCID to disown or claim papers
Loading papers...